抗结核固定剂量复合制剂的抗结核活性研究

目的对不同配方的抗结核固定剂量复合制剂的体内外抗结核活性进行研究并对其抗结核作用进行评估。方法体外活性用2倍稀释法检测最低抑菌浓度(MIC),体内活性以半数动物存活时间为指标观察药物对实验性结核病的疗效。结果2药或3药复合中的各药物对结核分枝杆菌H₃₇Rv、牛型结核杆菌(Ravenal)和草分枝结核杆菌(M.phlei)的MIC绝大多数都低于药物单独应用时的MIC;体内抗结核作用显示,2药复合和3药复合及其复合制剂对实验性结核病均表现出显著的治疗作用,并明显优于各配方中相应药物单独应用时的作用。结论2药复合和3药复合及其制剂在体内外均具有显著抗结核作用,且不同厂家的同一产品的抗结核作用未见显著差异。

Study on the activity of the Fixed-dose combination in antituberculous

Objective To compare the antituberculous activities of the Fixed-dose combination(FDC) in antituberculous made by different pharmaceutical companies and evaluate their potential contribution to treatment of tuberculosis. Methods The MICs of the FDC against M.tuberculosis H₃₇Rv、M.phlei and M.ravenal were determined by the tube doubling dilution method in vitro.The efficacy of antituberculosis was assessed by half survival time of the mice. Results In vitro, the MICs of main composition in the FDC(RFP,INH or RFP,INH PZA) against M.tuberculosis H37Rv、M.phlei and M.ravenal were lower than that of each composition used alone in the same media.In vivo,these FDC drugs had marked effect against experimental tuberculosis in mice and were superior to each agent used alone with the same dose. Conclusion The two-and three-drug FDC had significantly effective antituberculous activity.The same preparations from different companies had not significant difference in treatment of the mice infected with M.tuberculosis.